Key facts
- CancerNavigator’s last known valuation is $28.0M (Feb 2026).
- It has raised $7.0M across 1 recorded rounds; the latest was Early Stage VC ($7.0M) in Dec 2025.
- Notable investors include Oncology Ventures.
- CancerNavigator has filed 1 Form D with the SEC, most recently Feb 2026 ($7.0M sold to 8 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for CancerNavigator
Funding rounds
1 roundsAbout CancerNavigator
Provider of cancer navigation and analytics services intended to offer the guidance and support patients need. The company provides deep research to patients on their situation, offers options they have nearby, and also offers customized services, enabling patients reach experts for their care.
- Sector
- Healthcare
- HQ
- Washington, DC, United States
- Founded
- 2019
- Employees
- 25
- Website
- cancernavigator.com/
- Ownership
- Privately Held (backing)
CancerNavigator doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in CancerNavigator shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on CancerNavigator in its N-PORT filings yet. We sweep new filings monthly.